Infanrix vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):
-
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
- Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
- Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
- Serious allergic reaction to a previous pertussis vaccination;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy;
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Infanrix vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
- If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Infanrix should be carefully considered prior to vaccination;
- The tip caps of prefilled Infanrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex.
INFANRIX is FDA approved for use in infants and children between six weeks through six years of age. INFANRIX should not be administered to infants younger than six weeks or children older than six years of age.
